AI Portfolio Summary
In 2025 Q4, BRAIDWELL LP maintained a portfolio of 93 distinct positions. The most significant new addition to the portfolio was KODIAK SCIENCES INC, which now represents 1.85% of the total fund value. They heavily accumulated shares in CARIS LIFE SCIENCES , increasing their position by 6.8%. The fund also reduced its exposure to DANAHER CORPORATION by 61.8%.
Total Positions
93
Quarter
2025 Q4
Top Holding
CAI (6.7%)
Top 10 Concentration
37.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 93
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CAI
CARIS LIFE SCIE...
|
Healthcare | 6.74% | 6.57% |
#1
1
Prev: #2
|
6.7 | 500,000 | 6.8% |
P
S
|
7,816,142 | $210,879,512 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
GUARDANT HEALTH...
|
—
|
Bond/Debt | 6.15% | 8.49% |
#2
1
Prev: #1
|
4.0 | -114,600,000 | -52.2% |
P
S
|
104,854,000 | $192,312,721 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 4.14% | 2.51% |
#3
10
Prev: #13
|
3.7 | no change | no change |
P
S
|
5,210,831 | $129,306,771 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
REPLIGEN CORP
|
—
|
Bond/Debt | 3.54% | 3.02% |
#4
3
Prev: #7
|
2.9 | no change | no change |
P
S
|
101,000,000 | $110,847,500 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 3.41% | 3.67% |
#5
1
Prev: #6
|
2.4 | -128,748 | -14.6% |
P
S
|
751,534 | $106,590,067 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GKOS
GLAUKOS CORP
|
Healthcare | 3.33% | 1.89% |
#6
10
Prev: #16
|
3.3 | 141,815 | 18.2% |
P
S
|
921,979 | $104,100,649 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
NEOGENOMICS INC
|
—
|
Bond/Debt | 2.87% | 2.58% |
#7
3
Prev: #10
|
2.1 | no change | no change |
P
S
|
100,381,000 | $89,715,519 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
NUVL
NUVALENT INC
|
Healthcare | 2.64% | 2.60% |
#8
1
Prev: #9
|
1.6 | -191,576 | -18.9% |
P
S
|
821,406 | $82,625,230 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.62% | 4.29% |
#9
5
Prev: #4
|
1.0 | -1,779,953 | -49.4% |
P
S
|
1,825,076 | $81,799,906 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 2.48% | 3.92% |
#10
5
Prev: #5
|
1.0 | -1,412,746 | -43.0% |
P
S
|
1,870,571 | $77,666,108 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
IRHYTHM TECHNOL...
|
—
|
Bond/Debt | 2.33% | 2.53% |
#11
1
Prev: #12
|
1.4 | -10,000,000 | -16.1% |
P
S
|
52,000,000 | $72,800,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
HNGE
HINGE HEALTH IN...
|
Healthcare | 1.94% | 1.33% |
#12
13
Prev: #25
|
3.3 | 394,147 | 43.3% |
P
S
|
1,304,623 | $60,599,738 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALGN
ALIGN TECHNOLOG...
|
Healthcare | 1.90% | 1.52% |
#13
10
Prev: #23
|
1.3 | -28,687 | -7.0% |
P
S
|
381,004 | $59,493,775 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KOD
KODIAK SCIENCES...
|
Healthcare | 1.85% | — |
#14
Prev: #—
|
4.2 | 2,072,788 | no change |
NEW
|
2,072,788 | $57,955,152 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 1.76% | 2.57% |
#15
4
Prev: #11
|
1.2 | -94,130 | -7.3% |
P
S
|
1,187,859 | $54,997,872 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 1.75% | — |
#16
Prev: #—
|
4.2 | 2,188,320 | no change |
NEW
|
2,188,320 | $54,729,883 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NEO
NEOGENOMICS INC
|
Healthcare | 1.74% | 0.41% |
#17
43
Prev: #60
|
3.7 | 2,861,655 | 161.6% |
P
S
|
4,632,801 | $54,481,740 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 1.74% | 1.51% |
#18
6
Prev: #24
|
1.2 | -346,634 | -14.6% |
P
S
|
2,032,021 | $54,275,281 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 1.71% | 1.28% |
#19
7
Prev: #26
|
0.7 | -943,789 | -36.6% |
P
S
|
1,634,615 | $53,549,987 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 1.68% | 0.97% |
#20
13
Prev: #33
|
3.7 | 438,878 | 52.6% |
P
S
|
1,273,935 | $52,498,861 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
IRONWOOD PHARMA...
|
—
|
Bond/Debt | 1.61% | 2.16% |
#21
7
Prev: #14
|
0.6 | -28,735,000 | -35.0% |
P
S
|
53,405,000 | $50,467,725 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 1.61% | 0.45% |
#22
33
Prev: #55
|
3.6 | 1,266,420 | 214.0% |
P
S
|
1,858,109 | $50,466,240 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSP
INSPIRE MED SYS...
|
Healthcare | 1.60% | 1.95% |
#23
8
Prev: #15
|
0.6 | -342,857 | -38.8% |
P
S
|
540,890 | $49,886,285 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 1.59% | 2.73% |
#24
16
Prev: #8
|
0.6 | -318,300 | -61.2% |
P
S
|
202,101 | $49,825,981 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 1.51% | 1.73% |
#25
6
Prev: #19
|
0.6 | -46,810 | -35.9% |
P
S
|
83,417 | $47,244,052 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TMO
THERMO FISHER S...
|
Healthcare | 1.50% | 1.64% |
#26
4
Prev: #22
|
0.6 | -33,208 | -29.1% |
P
S
|
80,725 | $46,776,101 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BTSG
BRIGHTSPRING HE...
|
Healthcare | 1.43% | — |
#27
Prev: #—
|
4.1 | 1,195,786 | no change |
NEW
|
1,195,786 | $44,782,186 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CVS
CVS HEALTH CORP
|
Healthcare | 1.43% | 0.98% |
#28
4
Prev: #32
|
3.1 | 125,600 | 28.6% |
P
S
|
564,200 | $44,774,912 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 1.39% | 1.70% |
#29
9
Prev: #20
|
0.6 | -863,678 | -60.0% |
P
S
|
575,067 | $43,406,057 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 1.32% | — |
#30
Prev: #—
|
4.0 | 2,183,864 | no change |
NEW
|
2,183,864 | $41,427,900 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.27% | 0.41% |
#31
28
Prev: #59
|
3.5 | 312,003 | 66.0% |
P
S
|
784,742 | $39,739,335 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRTC
IRHYTHM TECHNOL...
|
Healthcare | 1.23% | 1.15% |
#32
4
Prev: #28
|
1.0 | -8,500 | -3.8% |
P
S
|
217,345 | $38,565,697 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TMDX
TRANSMEDICS GRO...
|
Healthcare | 1.23% | 1.17% |
#33
6
Prev: #27
|
1.0 | -35,907 | -10.2% |
P
S
|
315,341 | $38,361,233 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 1.14% | 0.85% |
#34
1
Prev: #35
|
2.5 | 73,520 | 13.9% |
P
S
|
601,520 | $35,748,334 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ILMN
ILLUMINA INC
|
Healthcare | 1.13% | — |
#35
Prev: #—
|
4.0 | 269,673 | no change |
NEW
|
269,673 | $35,370,311 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 1.13% | 0.46% |
#36
16
Prev: #52
|
3.5 | 177,567 | 64.2% |
P
S
|
454,259 | $35,345,893 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 1.11% | 0.06% |
#37
33
Prev: #70
|
3.4 | 2,841,734 | 1294.7% |
P
S
|
3,061,222 | $34,622,421 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PEN
PENUMBRA INC
|
Healthcare | 1.10% | 1.06% |
#38
9
Prev: #29
|
0.4 | -31,376 | -22.2% |
P
S
|
110,152 | $34,247,358 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.03% | — |
#39
Prev: #—
|
3.9 | 1,018,600 | no change |
NEW
|
1,018,600 | $32,126,644 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 1.01% | — |
#40
Prev: #—
|
3.9 | 929,694 | no change |
NEW
|
929,694 | $31,488,736 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDNA
CAREDX INC
|
Healthcare | 0.96% | 0.94% |
#41
7
Prev: #34
|
0.4 | -597,561 | -27.4% |
P
S
|
1,585,220 | $29,865,545 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.92% | 1.02% |
#42
11
Prev: #31
|
0.4 | -1,252,152 | -45.9% |
P
S
|
1,478,329 | $28,916,115 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 0.90% | 0.46% |
#43
10
Prev: #53
|
2.9 | 865,000 | 38.2% |
P
S
|
3,131,319 | $28,275,811 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 0.90% | 1.77% |
#44
26
Prev: #18
|
0.4 | -528,013 | -28.9% |
P
S
|
1,298,142 | $28,221,607 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRVI
MARAVAI LIFESCI...
|
Healthcare | 0.87% | 0.71% |
#45
4
Prev: #41
|
1.3 | no change | no change |
P
S
|
8,353,287 | $27,148,183 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
DANAHER CORPORA...
|
Healthcare | 0.87% | 1.82% |
#46
29
Prev: #17
|
0.3 | -191,112 | -61.8% |
P
S
|
118,227 | $27,064,525 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE
|
Healthcare | 0.83% | 1.67% |
#47
26
Prev: #21
|
0.3 | -45,084 | -59.3% |
P
S
|
31,007 | $26,075,337 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Healthcare | 0.82% | — |
#48
Prev: #—
|
3.8 | 111,500 | no change |
NEW
|
111,500 | $25,543,535 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 0.81% | 0.55% |
#49
1
Prev: #48
|
2.3 | 20,673 | 6.8% |
P
S
|
324,358 | $25,312,898 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.74% | — |
#50
Prev: #—
|
3.8 | 575,321 | no change |
NEW
|
575,321 | $23,242,968 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 93 holdings